Agilent Technologies, Inc. (NYSE:A) signed an agreement to acquire Multiplicom N.V. from Biotech Fund Flanders managed by Participatiemaatschappij Vlaanderen NV, GIMV NV (ENXTBR:GIMB) and others for €68 million in cash on December 19, 2016. Participatiemaatschappij Vlaanderen NV and GIMV NV held combined 42% stake in Multiplicom. Until the agreement closes, Multiplicom and Agilent will remain separate companies with each conducting business as usual. Multiplicom team will join the Genomics Division of Agilent's Diagnostics and Genomics Group. The transaction is subject to local laws and regulations and customary closing conditions and is expected to be completed by mid-January 2017.

Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Multiplicom N.V. from Biotech Fund Flanders managed by Participatiemaatschappij Vlaanderen NV, GIMV NV (ENXTBR:GIMB) and others for €72 million on January 20, 2017.